Smith & Nephew books Q1 sales slightly better than projections

The British medtech firm and Coloplast rival, Smith & Nephew, goes up on the London stock exchange after publicizing its Q1 figures.
Smith & Nephew has a good day on the stock exchange in London after delivering better-than-expected sales figures from Q1
Smith & Nephew has a good day on the stock exchange in London after delivering better-than-expected sales figures from Q1
by marketwire, translated by daniel pedersen

Following Smith & Nephew’s first quarterly report from 2022, the company’s stock price increased 2.4 percent to GBP 12.99 on the London stock exchange.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading